Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse

Trial Profile

A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin; Pegfilgrastim
  • Indications Leiomyosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2020 Updated results of progression-free survival (PFS) and final results of overall survival (OS) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 14 May 2020 According to a PharmaMar media release, data from this trial will be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29th to June 2nd , 2020.
    • 15 May 2014 A results of this study assessing the association between febrile neutropenia and skeletal muscle mass (SMM) and skeletal muscle densities (SMD) presented at the 2014 Annual Meeting of the ASCO, according to a PharmaMar media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top